# PETHEMA-BLIN-01/PET069014 (BLIN-01)

> **NCT03523429** · PHASE2 · TERMINATED · sponsor: **PETHEMA Foundation** · enrollment: 11 (actual)

## Conditions studied

- Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL

## Interventions

- **DRUG:** blinatumomab

## Key facts

- **NCT ID:** NCT03523429
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-30
- **Primary completion:** 2019-12-24
- **Final completion:** 2022-03-09
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Low rate of recruitment
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523429, "PETHEMA-BLIN-01/PET069014 (BLIN-01)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03523429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*